University of Debrecen Reports Findings in Atrial Fibrillation (Mortality on DOACs Versus on Vitamin K Antagonists in Atrial Fibrillation: Analysis of the Hungarian Health Insurance Fund Database): Heart Disorders and Diseases – Atrial Fibrillation

2023 APR 25 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- New research on Heart Disorders and Diseases - Atrial Fibrillation is the subject of a report. According to news reporting originating from Debrecen, Hungary, by NewsRx correspondents, research stated, “Limited real-world data are available on the survival of patients treated with vitamin K antagonists (VKAs) versus with direct oral anticoagulants (DOACs) for nonvalvular atrial fibrillation (AF). In this nationwide registry, we analyzed the mortality risk of patients with nonvalvular AF taking DOACs versus VKAs, with a special attention to the early treatment period.”

Our news editors obtained a quote from the research from the University of Debrecen, “The Hungarian National Health Insurance Fund (NHIF) database was searched to identify patients treated with VKA or DOAC as a thromboembolic prophylaxis for nonvalvular AF between 2011 and 2016. The overall and the early (0-3, 4-6, and 7-12 months) mortality risks with the 2 types of anticoagulation were compared. A total of 144,394 patients with AF treated with either a VKA (n = 129,925) or a DOAC (n = 14,469) were enrolled. A 28% improvement in 3-year survival with DOAC treatment compared with VKA treatment was shown. Mortality reduction with DOACs was consistent across different subgroups. However, younger patients (30-59 years old) initiated on DOAC therapy had the greatest RRR (53%) in mortality. Furthermore, DOAC treatment also yielded a benefit of greater magnitude (HR = 0.55; 95% CI, 0.40-0.77, P = 0.001) in the lower (0-1) CHADS-VASc score segment and in those with fewer (0-1) bleeding risk factors (HR = 0.50, CI 0.34-0.73, P = 0.001). The RRR in mortality with DOACs was 33% within the first 3 months, and 6% in the second year. Thromboembolic prophylaxis with DOACs in this study yielded significantly lower mortality compared with VKA treatment in patients with nonvalvular AF.”

According to the news editors, the research concluded: “The largest benefit was shown in the early period after treatment initiation, as well as in younger patients, those with a lower CHADS-VASc score, and those with fewer bleeding risk factors.”

This research has been peer-reviewed.

For more information on this research see: Mortality on DOACs Versus on Vitamin K Antagonists in Atrial Fibrillation: Analysis of the Hungarian Health Insurance Fund Database. Clinical Therapeutics, 2023. Clinical Therapeutics can be contacted at: Elsevier, 685 Route 202-206, Bridgewater, NJ 08807, USA. (Elsevier - www.elsevier.com; Clinical Therapeutics - http://www.journals.elsevier.com/clinical-therapeutics/)

The news editors report that additional information may be obtained by contacting Timea Papp, Dept. of Cardiology, Faculty of Medicine Debrecen, University of Debrecen, Debrecen, Hungary. Additional authors for this research include Zoltan Kiss, Gyorgy Rokszin, Ibolya Fabian, Laszlo Mark, Zsuzsa Bagoly, David Becker, Bela Merkely, Daniel Aradi, Csaba Andras Dezsi, Zoltan Jarai and Zoltan Csanadi.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.clinthera.2023.03.008. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Publisher contact information for the journal Clinical Therapeutics is: Elsevier, 685 Route 202-206, Bridgewater, NJ 08807, USA.

(Our reports deliver fact-based news of research and discoveries from around the world.)